Clovis, CEO Mahaffy Settle SEC Investor Fraud Charges Over Rociletinib Efficacy Claims
Executive Summary
Clovis, CEO Patrick Mahaffy and former CFO Erie Mast will pay more than $20m to settle charges by the SEC that the company misled investors on the efficacy of rociletinib. Clovis raised $298m in a public stock offering during the timeframe SEC says it misled investors.
You may also be interested in...
Tivozanib Communications Come Back To Haunt Aveo, Former Execs
Company pays $4m to settle SEC claims that it failed to publicly disclose FDA's May 2012 recommendation for a new trial of its tyrosine kinase inhibitor, the subject of a negative advisory committee review a year later. Fraud claims against three former officers continue.
Clovis Crumbles On Data Disclosure, Possible FDA Delay
Investors' hopes for an early approval of Clovis Oncology Inc.'s experimental lung cancer drug rociletinib were crushed on Nov. 16 after the company disclosed the drug's response rates were much lower than the firm had earlier reported.